领诺

Linnuo Pharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies targeting the complement system to treat rare and severe diseases. The company leverages its proprietary platform to develop next-generation complement inhibitors with improved efficacy and delivery profiles compared to existing treatments. Its lead programs target key components of the complement cascade, including C3 and C5, for indications in hematology, neurology, and ophthalmology. Linnuo Pharma aims to address significant unmet medical needs in chronic inflammatory and autoimmune disorders through precision modulation of the innate immune response.